Verzenio (abemaciclib)
pCPA File Number:
23271
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. • as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy...
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CDA-AMC Project Number:
PC0409-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable